PulmonologyNews.net

Pulmonology Xagena

Search results for "LAMA"

Chronic obstructive pulmonary disease ( COPD ) is characterized by persistent airflow limitation caused by bronchial alterations, small airways disease and parenchymal destruction. In patients with CO ...


Two once-daily long-acting muscarinic antagonists ( LAMAs ) are currently available for the treatment of chronic obstructive pulmonary disease ( COPD ), Tiotropium ( Spiriva ) and Glycopyrronium ( See ...


Glycopyrronium bromide ( NVA237; Seebri Breezhaler ) is a once-daily long-acting muscarinic antagonist ( LAMA ) in development for chronic obstructive pulmonary disease ( COPD ). The GLOW2 ( GLyco ...


Inhaled Glycopyrronium bromide ( Seebri Breezhaler; NVA237 ) is a once-daily, long-acting muscarinic receptor antagonist ( LAMA ) that is approved in several countries, as a maintenance bronchodilator ...


Results from two phase III studies were presented. They have shown that patients with chronic obstructive pulmonary disease ( COPD ) who received the anticholinergic, Incruse Ellipta ( Umeclidinium 62 ...


Dual bronchodilation with a long-acting beta2-agonist ( LABA ) and long-acting muscarinic antagonist ( LAMA ) is recommended for patients with a high symptomatic burden and/or risk of exacerbations ( ...


Results from a third lung function study comparing the efficacy and safety of Umeclidinium and Vilanterol ( Anoro Ellipta; UMEC/VI ), a combination long-acting muscarinic antagonist ( LAMA ) / long-ac ...


Aclidinium bromide / Formoterol fumarate ( 400/12 mcg ) is a fixed dose combination of two approved long-acting bronchodilators with different mechanisms of action and similar pharmocodynamic profiles ...


Multidrug-resistant and extensively drug-resistant tuberculosis ( TB ) are associated with worse treatment outcomes for patients, including higher mortality, than for drug-sensitive tuberculosis. ...